Imatinib ▼ (Glivec® ▼) – Kit-positive unresectable and /or metastatic GIST

Drug Name (Brand)	Imatinib ▼ *(Glivec® ▼)*
Indication	Kit-positive unresectable and /or metastatic GIST
Traffic Light Classification	Red
NICE TA (plus link)	Overview \| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours \| Guidance \| NICE
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. January 2011: The TAG acknowledged NICE Technology Appraisal 209 (partial update of TA 86) as follows: Imatinib at 600 or 800 mg/day is not recommended for people with unresectable and/or metastatic gastrointestinal stromal tumours whose disease has progressed after treatment with 400 mg/day imatinib. People who are currently receiving 600 or 800 mg/day imatinib for unresectable and/or metastatic gastrointestinal stromal tumours should have the option to continue therapy until they and their clinicians consider it appropriate to stop. November 2013: Commissioning responsibility of NHS England SCG from April 2013. Cancer Drugs Fund List Sept 2013 – http://www.england.nhs.uk/wp-content/uploads/2013/09/ncdf-list-sept.pdf
Date of TAG recommendation / ratification		1/1/2011	Review Date